Stocktoria
Grace Therapeutics, Inc. GRCE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-03-07
Grace Therapeutics, Inc. statistics & valuation
Market cap$38.7M
P / B0.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Operating margin | — | — | — | — | -15.6% |
| Net margin | — | — | — | — | -9.8% |
| Return on assets | -11.7% | -13.3% | -17.5% | -53.6% | -7.6% |
| Return on equity | -12.2% | -14.4% | -20.8% | -62.4% | -9.1% |
| Current ratio | 8.10 | 11.77 | 14.26 | 8.59 | 13.89 |
| Revenue growth | — | — | — | — | 50920.4% |
Source: SEC EDGAR filings · CIK 0001444192 · as of 2026-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.